Qualigen Therapeutics Inc
NASDAQ:QLGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Qualigen Therapeutics Inc
NASDAQ:QLGN
|
US |
|
Cellnex Telecom SA
LSE:0R9C
|
ES |
|
P
|
Ping An Insurance Group Co of China Ltd
OTC:PIAIF
|
CN |
|
W
|
Wellchange Holdings Co Ltd
NASDAQ:WCT
|
HK |
|
J
|
Jet.AI Inc
NASDAQ:JTAI
|
US |
|
S
|
Sleeping Giant Capital Corp
XTSX:SSX.P
|
CA |
|
S
|
Suzhou Secote Precision Electronic Co Ltd
SSE:603283
|
CN |
|
B
|
Boombit SA
WSE:BBT
|
PL |
|
I
|
Ilyda SA
ATHEX:ILYDA
|
GR |
|
Bonesupport Holding AB
STO:BONEX
|
SE |
|
S
|
Synergia Energy Ltd
ASX:SYN
|
AU |
Qualigen Therapeutics Inc
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company is headquartered in Los Angeles, California and currently employs 39 full-time employees. The company went IPO on 2015-06-24. The firm's cancer therapeutics pipeline includes QN-302, QN-247 and RAS-F. QN-302 compound is a small molecule genomic quadruplex (G4) selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. RAS-F is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins and preventing this binding to stop tumor growth, especially in RAS-driven tumors such as pancreatic, colorectal and lung cancers. Its pipeline also includes QN-165, a drug candidate for treating COVID-19 and other viral-based infectious diseases.
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company is headquartered in Los Angeles, California and currently employs 39 full-time employees. The company went IPO on 2015-06-24. The firm's cancer therapeutics pipeline includes QN-302, QN-247 and RAS-F. QN-302 compound is a small molecule genomic quadruplex (G4) selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. RAS-F is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins and preventing this binding to stop tumor growth, especially in RAS-driven tumors such as pancreatic, colorectal and lung cancers. Its pipeline also includes QN-165, a drug candidate for treating COVID-19 and other viral-based infectious diseases.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
